Markets

Integrated Solutions for RNA-based Drugs

The increasing use of RNA-based drugs is driving new requirements for pharmaceutical development, manufacturing, and supply chain management. Vial formats can support faster time-to-market, while pre-fillable syringe formats can help improve dosing accuracy and ease of use.

However, RNA-based therapies require careful evaluation of container closure systems, cold storage performance, and lifecycle management. Stevanato Group supports RNA drug developers with a science-based, integrated approach designed to reduce risk, support product stability, and accelerate time to market.

RNA drug features and key challenges

RNA molecules are typically encapsulated in lipid nanoparticles, which can be highly sensitive to particulates and can interact with the container closure system. This creates important technical considerations across development, manufacturing, storage, and administration.

Key challenges include:

Managing deep-cold storage requirements

Supporting lifecycle management from development to commercialization

Ensuring drug product stability over time

Reducing risks related to particulates and container closure systems

Integrating complex technology platforms, such as lipid nanoparticle formulation

Stevanato Group can serve RNA-based drug production processes with comprehensive solutions covering the full pharma value chain.
Our unique position in the market enables us to be an integrated provider of primary packaging, machinery, and analytical services.

Stevanato Group is the right partner for RNA technology because we can help reduce the time to market, with a single interface providing right first time solutions.

Discover our solutions designed to support RNA-based drugs and mRNA therapies, from clinical development to commercial manufacturing.